Quercetin (Senolytic).

Both are flavonols reported to act on the anti-apoptotic survival networks senescent cells depend on, including BCL-2 family signalling. They hit overlapping but not identical nodes, so the pair is common in senolytic formulation.

Resveratrol acts on sirtuin and AMPK signalling while quercetin acts on senescent cell survival pathways. Quercetin also competes for the sulfotransferase and glucuronidase enzymes that clear resveratrol, which raises circulating resveratrol.

Pterostilbene is the dimethylated stilbene analogue with slower phase II clearance than resveratrol. It runs the same sirtuin and AMPK signalling alongside quercetin's separate senescence route.

Curcumin and quercetin both dampen NF-kB driven signalling, the pathway behind the secretory phenotype of senescent cells. Curcumin also competes for the same glucuronidation enzymes, which slows quercetin clearance.

Spermidine induces autophagy through hypusination and acetyltransferase inhibition, clearing damaged components inside living cells. Quercetin acts on the survival signalling of cells that have already become senescent.

Urolithin A drives mitophagy, the selective recycling of worn mitochondria. That maintenance route is separate from quercetin's action on senescent cell survival signalling.

Nicotinamide riboside raises NAD+ available to sirtuins and PARPs, supporting repair capacity in healthy cells. Quercetin works on the senescent cell population rather than on NAD+ supply.

Quercetin inhibits catechol-O-methyltransferase and efflux transporters that clear EGCG, so circulating EGCG runs higher when the two are taken together. Both are polyphenols acting on overlapping redox signalling.

When quercetin quenches a radical it becomes a quercetin radical itself. Ascorbate donates an electron to return it to the reduced form, so the flavonoid can act again.

Quercetin is heavily conjugated by UGT and SULT enzymes in the gut wall and liver. Piperine inhibits those conjugating enzymes and P-glycoprotein efflux, raising the fraction reaching circulation.

Quercetin is poorly water soluble and dissolves badly in intestinal fluid. Phospholipid complexation into a phytosome improves dispersion and absorption, which is why lecithin-bound forms exist.

The catechol group on quercetin binds iron tightly, forming complexes that are not taken up by the enterocyte. Non-heme iron absorption falls when a flavonol is taken in the same serving.

Quercetin can carry zinc ions across lipid membranes, raising intracellular zinc without a transporter. That ionophore behaviour is why the two are formulated together.

Dihydrolipoic acid regenerates ascorbate and glutathione, which in turn recycle oxidised flavonoids. It sits upstream in the same recycling chain quercetin depends on.

Tocopherol handles radicals inside the lipid membrane while quercetin works at the membrane surface and in aqueous compartments. The tocopheroxyl radical formed is reduced again by ascorbate in the same network.

Rutin itself is poorly absorbed intact and is hydrolysed mainly by colonic bacteria, which release the aglycone further down the gut and later than an aglycone dose would appear. The two therefore give different absorption timing from the same eventual molecule. Rutin is also the industrial starting material most quercetin is made from.

Catechol-containing flavonoids bind divalent transition metals, which is part of how quercetin limits metal-catalysed oxidation. The same binding can reduce the fraction of a copper dose available for absorption when the two are taken together. Established coordination chemistry; the size of the absorption effect in people is not established.

When quercetin is oxidised it forms a reactive quinone that glutathione traps, which is one of the routes by which quercetin is cleared. At high exposures this consumes glutathione rather than sparing it. The relationship is real and it runs in both directions depending on dose, which is why it is recorded as modulating.

Reviews of polyphenol senotherapeutics group these flavonoids by shared mechanism rather than by tested combination. Both are also substrates for the same phase II conjugating enzymes, so they compete for clearance as well as adding at the target. Cell-level reasoning only.

Apigenin and quercetin appear together in mechanistic surveys of polyphenols acting on senescent cell signalling. No human combination data exists. Both compete for sulfation and glucuronidation capacity.

Reviews of ageing interventions place NAD repletion and senescent cell clearance side by side as distinct mechanisms. The pairing is conceptual and preclinical. It has not been tested as a combination in people.

Sulforaphane modifies Keap1 cysteines directly, while quercetin is described as an indirect Nrf2 activator in cell systems. Two routes to one transcription factor may add or may saturate; that has not been measured in people.

Berberine has low oral availability because efflux transport and first-pass metabolism remove most of it, and quercetin inhibits both routes in laboratory systems. Co-administration would therefore be expected to raise berberine exposure rather than leave it unchanged, though this has not been quantified in people. Because that same inhibition applies to medicines cleared the same way, it is a caution as much as a synergy.

Silymarin flavonolignans and quercetin are conjugated by overlapping phase II enzymes, so taken together they compete for the same clearance capacity. That can raise exposure to either one unpredictably. Inferred from in vitro enzyme work, not measured in a combination study.

Quercetin aglycone is poorly water soluble, and food-matrix fat improves its dissolution and micellar uptake. A medium-chain triglyceride carrier is one practical version of that. Direction is supported by physicochemistry; no number for the pairing is established.

Quercetin is a weak phosphodiesterase inhibitor in vitro at concentrations that oral dosing does not clearly reach. This is a laboratory overlap and should not be read as an additive stimulant effect in people.

Thyroid peroxidase uses iodide in normal hormone synthesis, and in vitro work reports flavonoid inhibition of that enzyme. The concentrations used are typically well above what oral flavonoid intake produces, and human data is absent. Recorded so the interaction is visible, at the confidence the evidence actually supports.